- Prev close
- $798.17
- Day range
- $791.31 – $811.66
- Next earnings
- in 34 days
REGN rose +1.9% even as the S&P 500 gained +1.1% and peers ABBV, AMGN and GILD also advanced, so the session reads as orderly rather than event-driven. The stock still sits 8.1% below its 52-week high, with solid growth and a 14.1 forward P/E keeping the setup mixed.
REGN
REGENERON PHARMACEUTICALS
As of Sep 17, 2026
58/100
Worth keeping an eye onHealth ScoreMove driver
The primary driver looks market- and sector-wide, not stock-specific: REGN closed +1.9% while the S&P 500 rose +1.1%, the Nasdaq 100 rose +1.7%, and same-sector peers ABBV +0.6%, AMGN +0.9%, and GILD +2.2% all moved higher. That puts REGN near the upper end of the day’s range — open $781.18, high $789.99, low $774.775, close $789.45 — and the move reads as participation in a broader healthcare bid rather than a company-specific rerating.
Volatility check
This looks like ordinary volatility for a low-beta large cap, not a change in business quality: beta is 0.14, revenue is +9.3% YoY (TTM) and +16.7% YoY in the latest quarter, and margins remain strong at gross +86.0%, operating +24.7%, and net +27.9%. Valuation is not cheap at PE 18.6 and forward PE 14.1, but PEG 1.08 is still close to growth-adjusted fair value because earnings growth is positive; that means the stock can move, but the move is not being driven by deteriorating fundamentals. The recent +1.9% session is therefore consistent with normal trading around a profitable, steadily growing name rather than evidence of a new problem.
Earnings preview
The next earnings date is 2026-10-26. The facts do not include analyst revenue or EPS consensus for that print, so I cannot quote a third-party forecast for the upcoming quarter here; what is available is the current operating base: revenue +9.3% YoY (TTM), latest quarter +16.7% YoY, EPS +1.9% YoY (TTM), with gross margin +86.0% and operating margin +24.7%. The market is likely watching three concrete items: whether the latest-quarter +16.7% revenue pace holds, whether EPS growth can improve beyond +1.9% YoY, and whether any pipeline updates alter sentiment after the September 2026 class-action lawsuits tied to the Fianlimab-Libtayo trial narrative.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track REGN with WhyIHold
Get a plain-English explanation the next time REGENERON PHARMACEUTICALS makes a big move — so you know whether it's benign or worth your attention.